1 citations
,
October 2014 in “Skin Pharmacology and Physiology” This study found that osteopontin expression was significantly higher in alopecia areata lesions compared to healthy controls, suggesting it may play a role in the disease's pathogenesis.
6 citations
,
May 2016 in “Urolithiasis” This study found that the risk of urinary stone disease increased significantly in patients with severe androgenetic alopecia, and that testosterone deficiency was more frequent among these patients.
April 2018 in “Journal of Investigative Dermatology” The researchers reported that in nonmelanoma skin cancers, the expression of osteopontin splice variants is significantly higher compared to normal skin, with OPN-a elevated in basal cell carcinoma more than OPN-c.
September 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” In this study, FOL-026, a peptide based on osteopontin, was shown to promote angiogenesis and stimulate vascular cell proliferation and migration through neuropilin-1, similar to VEGF, suggesting potential therapeutic applications in vascular repair and angiogenesis-related conditions.
April 2018 in “Journal of Investigative Dermatology” This study identified the osteopontin-derived peptide, FOL-005, as a potential inhibitor of unwanted human hair growth by promoting catagen development without reducing stem cell numbers or showing toxicity.